Rhumbline Advisers Has $2.92 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Rhumbline Advisers lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 113,561 shares of the company’s stock after purchasing an additional 585 shares during the period. Rhumbline Advisers owned 0.13% of IDEAYA Biosciences worth $2,919,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. KBC Group NV increased its position in IDEAYA Biosciences by 29.1% in the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock worth $72,000 after buying an additional 513 shares during the period. Amalgamated Bank grew its stake in shares of IDEAYA Biosciences by 22.9% in the third quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock worth $90,000 after acquiring an additional 530 shares during the last quarter. US Bancorp DE grew its stake in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after acquiring an additional 689 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in IDEAYA Biosciences by 35.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock worth $94,000 after acquiring an additional 796 shares during the period. Finally, Allworth Financial LP raised its stake in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 800 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on IDYA shares. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Stephens reaffirmed an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Leerink Partners cut IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Finally, Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Stock Performance

IDYA opened at $20.57 on Friday. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -6.23 and a beta of 0.82. The firm’s 50-day simple moving average is $23.30 and its 200-day simple moving average is $28.65. IDEAYA Biosciences, Inc. has a twelve month low of $19.95 and a twelve month high of $47.72.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.